
Peking University First Hospital has a total capacity of 1,805 beds across three campuses: Central, Miyun, and Daxing. The hospital delivers a full range of inpatient and outpatient services, serving patients across China and internationally.
Established in 1915, Peking University First Hospital (PUFH) is one of China's most prestigious medical institutions, affiliated with the Peking University Health Science Center. As a top-tier tertiary hospital classified as Grade 3A, it is recognized for its leadership in clinical excellence, education, and research. Over the decades, PUFH has been pioneering in shaping modern Chinese medicine, particularly in specialties such as urology, nephrology, pediatrics, neurology, cardiology, and organ transplantation.
The hospital is home to a team of highly qualified doctors and professors, including many national-level experts. Known for managing complex and rare diseases, it continues to advance patient care through innovation, multidisciplinary collaboration, and compassionate treatment.
Advanced Technology & Facilities
Key Services at Peking University First Hospital
Peking University First Hospital blends a century of medical heritage with high-quality clinical care, innovative research, and comprehensive education. It stands as a benchmark of excellence in China, committed to improving patient outcomes through multidisciplinary collaboration and compassionate, personalized care.

The hospital has approximately 50 inpatient beds in its main campus, along with nine satellite clinics across Beijing. It manages over 2,500 outpatient visits each week and provides care to hundreds of thousands of patients annually, both local and international.
Beijing United Family Hospital (BJU) is one of China’s most prestigious private medical institutions, known for delivering world-class healthcare that meets international standards. Established in 1997, it was the first foreign-invested hospital in China and has since become a trusted choice for both International and Chinese patients seeking high-quality, patient-focused care. As part of the United Family Healthcare network, BJU has built a reputation for medical excellence, advanced technology, and a uniquely personalized approach to treatment.
The hospital is staffed by a diverse team of internationally trained doctors, many of whom have practiced in top healthcare systems across the U.S., Europe, and Asia. This global expertise is complemented by the latest medical equipment, multilingual support services, and a strong commitment to clinical safety and patient satisfaction. Recognized by the Joint Commission International (JCI) for meeting the highest standards in healthcare delivery, BJU offers a full spectrum of medical services across numerous specialties, including family medicine, internal medicine, orthopedics, oncology, cardiology, obstetrics, pediatrics, and plastic surgery.
Advanced Technology & Facilities
Key Services at BJU
Beijing United Family Hospital stands as a pioneer in international-standard healthcare in China, blending modern technology, world-class medical expertise, and a warm, comprehensive approach to family health.

As part of Singapore‑listed Raffles Medical Group, founded in 1976, RMG China operates 5 tertiary hospitals and over 100 clinics, supported by 430+ physicians and 900+ nurses & allied health professionals, delivering comprehensive inpatient and outpatient services.
Raffles Medical Group has operated in China since 2010, growing into a trusted name among both local and expatriate communities. All RMG China hospitals and clinics follow the Group’s Institutional Group Practice Model, which emphasizes integrated, peer-reviewed, and clinically audited care. Backed by Raffles Hospital Singapore, accredited by Joint Commission International (JCI), the network ensures alignment with global standards for quality and patient safety. With a rigorous clinical governance framework, strategic insurance and corporate partnerships, and a presence in key Chinese cities, RMG serves over 2.8 million patients annually. The Group continues to expand across China, offering world-class healthcare that combines international expertise with localized, patient-centered care.
Advanced Technology & Facilities
Key Services at Raffles Medical Group China
Raffles Medical Group China is a leading integrated private hospital network, delivering high-quality, multidisciplinary medical care in major Chinese cities. With its robust institutional infrastructure, advanced diagnostic and treatment facilities, and a reputation anchored by the Singapore-based Raffles Hospital, RMG China continues to expand and uphold global healthcare standards.

GoBroad Healthcare Group, founded in 2017, is a leading medical network in China, specializing in the treatment of complex hematologic diseases and solid tumors. The group integrates clinical treatment, research, reference laboratories, and medical information technology under an Academic Research Organization model. With seven hospitals across Beijing, Shanghai, and Guangzhou, it provides advanced therapies including CAR-T cell therapy, hematopoietic stem cell transplantation, chemotherapy, radiotherapy, and targeted therapy. Its multidisciplinary teams ensure that patients receive comprehensive and personalized treatment for both common and rare conditions. The group is known for its patient-centered approach by combining modern medical science with innovative therapies and long-term follow-up care. With international collaborations, multilingual staff, and dedicated global patient services, it has become a trusted choice for individuals seeking specialized cancer and hematology treatments in China. By focusing on research-driven medicine, advanced facilities, and supportive care, GoBroad Healthcare Group continues to enhance patient survival, recovery, and long-term quality of life.
Advanced Technology & Facilities
Key Services



China is widely recognized for comprehensive care in hematologic malignancy due to its large scale academic hospitals, dedicated blood disease centers, and strong safety culture. Many clinics operate within nationally accredited institutions and follow structured clinical pathways that include detailed diagnostic testing, multidisciplinary review, and staged treatment planning. These systems help manage complex diseases such as leukemia, lymphoma, and multiple myeloma while maintaining consistent quality standards.
Treatment for hematologic malignancies in China typically ranges from USD 15,000 to USD 90,000. Costs vary based on disease type, treatment intensity, use of stem cell transplantation or cellular therapy, length of hospital stay, and the level of supportive care required. Recovery often follows a milestone based pattern. The first week focuses on close monitoring, the first month involves immune recovery and follow up testing, and return to regular routines may take several months depending on treatment complexity. Not every patient is an ideal candidate for advanced therapy, so individualized evaluation by the clinic team is essential.
This information is for educational purposes and does not replace an in person consultation with a qualified specialist.
Hematologic malignancy clinics in China are known for experienced multidisciplinary teams, high case volumes, and access to advanced diagnostics and treatment technologies. Many centers combine clinical care with active research programs, allowing patients to benefit from standardized protocols and evolving therapies within structured safety frameworks.
Peking University People’s Hospital Blood Disease Department in Beijing is one of the most respected centers for blood cancer care in China. As a National Clinical Research Center for Hematological Diseases, it manages large volumes of leukemia, lymphoma, and myeloma cases. The department is well known for stem cell transplantation programs, advanced molecular diagnostics, and strict infection control and follow up systems.
The Institute of Hematology and Blood Diseases Hospital of CAMS and PUMC in Tianjin is a specialized hospital focused entirely on blood disorders. It treats a very high number of patients each year and offers comprehensive care for leukemia, lymphoma, myelodysplastic syndromes, and transplantation. The hospital emphasizes standardized safety protocols, dedicated inpatient units, and long term outcome monitoring.
Shanghai Ruijin Hospital Hematology Department is a leading center in eastern China with strong clinical and scientific output. Its multidisciplinary teams manage complex hematologic malignancies using targeted therapies, transplant programs, and clinical trials, supported by modern laboratory and imaging services.
Best Clinic Abroad supports international patients who are considering hematologic malignancy treatment in China. The team helps connect you with verified clinics, clarify your options, and coordinate key details around your treatment journey.
➤ Initial virtual consultation - Arrange online discussions with selected clinics so specialists can review medical records and provide preliminary guidance.
➤ Clear package information - Request transparent cost estimates that outline typical inclusions such as hospital care, procedures, and follow up services.
➤ Medical file coordination - Help organize pathology reports, imaging, and laboratory results for clinic review before travel.
If you are exploring hematologic malignancy care in China, you can begin by sharing your case with Best Clinic Abroad and receive guided support in choosing a suitable clinic and planning next steps.
Question: What risks are associated with hematologic malignancy treatment
Answer: Risks can include infection, immune related reactions, and delayed recovery, which clinics manage through monitoring, supportive care, and structured follow up.
Question: How long do patients usually stay in China for treatment
Answer: Length of stay varies by treatment type and response, ranging from several weeks to a few months, depending on therapy intensity and recovery progress.